Eli Lilly to Buy Merida Biosciences for $2.88B in Autoimmune Push
Eli Lilly is acquiring Merida Biosciences for up to $2.88 billion in cash to strengthen its portfolio in autoimmune and allergic diseases. This strategic move reflects the company's effort to diversify beyond its highly successful weight-loss and diabetes franchises. The acquisition demonstrates Lilly's commitment to expanding its therapeutic reach despite already being the world's largest pharmaceutical company.
1 Article
Trace's outlet lean is shown first — tap Left / Center / Right on each source to add your rating too.
- BloombergTrace: Center
Lilly to Buy Merida for $2.88B in Autoimmune Push
Eli Lilly is acquiring Merida Biosciences for up to $2.88 billion in cash to strengthen its portfolio in autoimmune and allergic diseases. This strategic move reflects the company's effort to diversify beyond its highly successful weight-loss and diabetes franchises. The acquisition demonstrates Lilly's commitment to expanding its therapeutic reach despite already being the world's largest pharmaceutical company.
Rate outletRead original
Readers say
How does this story lean?
Outlet ratings above are Trace's curated source map. Vote here (same as on the home feed) — one vote per browser, changeable anytime. Rate individual outlets in the coverage list below.
Comments
0No comments yet. Say what you noticed in the coverage.